X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with IPCA Labs - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA IPCA LABS SHASUN PHARMA/
IPCA LABS
 
P/E (TTM) x 123.9 36.4 340.1% View Chart
P/BV x 8.5 2.8 305.5% View Chart
Dividend Yield % 0.2 0.2 126.7%  

Financials

 SHASUN PHARMA   IPCA LABS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
IPCA LABS
Mar-17
SHASUN PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs94643 14.7%   
Low Rs46503 9.1%   
Sales per share (Unadj.) Rs214.2254.4 84.2%  
Earnings per share (Unadj.) Rs5.316.1 33.2%  
Cash flow per share (Unadj.) Rs15.829.8 53.1%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %1.40.2 819.6%  
Book value per share (Unadj.) Rs53.3194.6 27.4%  
Shares outstanding (eoy) m56.62126.20 44.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.32.3 14.5%   
Avg P/E ratio x13.135.7 36.7%  
P/CF ratio (eoy) x4.419.2 23.0%  
Price / Book Value ratio x1.32.9 44.5%  
Dividend payout %18.76.2 301.2%   
Avg Mkt Cap Rs m3,95872,300 5.5%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m2,1646,960 31.1%   
Avg. sales/employee Rs ThNM2,413.5-  
Avg. wages/employee Rs ThNM523.2-  
Avg. net profit/employee Rs ThNM152.4-  
INCOME DATA
Net Sales Rs m12,12732,106 37.8%  
Other income Rs m229226 101.6%   
Total revenues Rs m12,35632,332 38.2%   
Gross profit Rs m1,0094,448 22.7%  
Depreciation Rs m5941,730 34.3%   
Interest Rs m415241 172.4%   
Profit before tax Rs m2302,703 8.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73675 -10.8%   
Profit after tax Rs m3022,028 14.9%  
Gross profit margin %8.313.9 60.1%  
Effective tax rate %-31.725.0 -126.7%   
Net profit margin %2.56.3 39.4%  
BALANCE SHEET DATA
Current assets Rs m6,88417,340 39.7%   
Current liabilities Rs m8,4569,559 88.5%   
Net working cap to sales %-13.024.2 -53.5%  
Current ratio x0.81.8 44.9%  
Inventory Days Days62100 61.4%  
Debtors Days Days10857 189.1%  
Net fixed assets Rs m4,97020,779 23.9%   
Share capital Rs m113252 44.9%   
"Free" reserves Rs m2,87524,499 11.7%   
Net worth Rs m3,02024,553 12.3%   
Long term debt Rs m1,8173,517 51.7%   
Total assets Rs m13,34739,595 33.7%  
Interest coverage x1.612.2 12.7%   
Debt to equity ratio x0.60.1 420.0%  
Sales to assets ratio x0.90.8 112.1%   
Return on assets %5.45.7 93.8%  
Return on equity %10.08.3 121.1%  
Return on capital %13.310.5 127.0%  
Exports to sales %46.448.6 95.3%   
Imports to sales %14.214.2 100.1%   
Exports (fob) Rs m5,62215,617 36.0%   
Imports (cif) Rs m1,7284,571 37.8%   
Fx inflow Rs m5,84315,617 37.4%   
Fx outflow Rs m2,1735,828 37.3%   
Net fx Rs m3,6699,790 37.5%   
CASH FLOW
From Operations Rs m3982,764 14.4%  
From Investments Rs m-1,635-1,432 114.2%  
From Financial Activity Rs m1,309-1,591 -82.2%  
Net Cashflow Rs m71-259 -27.5%  

Share Holding

Indian Promoters % 39.2 45.9 85.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.4 31.6%  
FIIs % 17.6 25.3 69.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.4 227.6%  
Shareholders   20,750 36,892 56.2%  
Pledged promoter(s) holding % 12.3 2.1 574.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Dull Start to the Week; Cement Stocks Tank(Closing)

Indian share markets continued to trade on a dull note in the afternoon session amid weak international markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Of Falling Real Estate Prices, Dr Arvind Panagariya and the Art of Continuing to Suck Up(Vivek Kaul's Diary)

Nov 13, 2017

Dr Panagariya claims real estate prices have fallen 25 per cent post demonetisation; the official data doesn't show anything like that.

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

Why I am the Biggest India Equity Bull on Planet Earth!(The Honest Truth)

Nov 16, 2017

If you have a dream, dream big...about the level of BSE 30 index in 2050!

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - DISHMAN PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS